Remdesivir News and Research

RSS

Scientists introduce SARS-CoV-2 phenotype screening for identifying novel antiviral drugs

Researchers introduced a phenotypic screening assay for identifying compounds with SARS-CoV-2 inhibition potential based on caspase 3/7 activation.

20 Jul 2022

Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

Researchers reported mutations in SARS-CoV-2 Delta and Omicron variants of concern infection cases treated with neutralizing monoclonal antibodies.

20 Jul 2022

Should siRNA-based antivirals be added to the COVID toolbox?

A recent study reviewed the existing treatment modalities, including vaccines and antivirals, for SARS-CoV-2 infection.

19 Jul 2022

Nitazoxanide drug found to be a potent inhibitor of several human coronaviruses

Researchers evaluated the activity of nitazoxanide against human coronaviruses (HCoVs).

18 Jul 2022

New approach could pave the way for development of pan-coronavirus antivirals

To put the COVID-19 pandemic in the rearview mirror and prevent other coronaviruses from causing havoc, the world needs an arsenal of measures to prevent and treat these infections.

13 Jul 2022

The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients

Scientists assessed the potential of tixagevimab–cilgavimab for treating hospitalized SARS-CoV-2 patients.

13 Jul 2022

Does high-dose inhaled nitric oxide improve respiratory function and outcomes among pregnant patients hospitalized with severe COVID-19 pneumonia?

Researchers demonstrated that inhaled nitric oxide 200 (iNO200) enhances oxygenation in pregnant COVID-19 patients with severe pneumonia.

13 Jul 2022

Monoclonal antibody treatment taken by hospitalized COVID-19 patients reduces mortality

A monoclonal antibody treatment taken by patients hospitalized with COVID-19 did not improve recovery time but did reduce deaths, according to a study published July 8 in The Lancet Respiratory Medicine.

8 Jul 2022

Study examines IMPACC trial results to understand clinical phenotypes of disease severity in hospitalized COVID-19 patients

In a recent article, longitudinal clinical phenotypes were described based on respiratory ordinal scales.

7 Jul 2022

Remdesivir resistance in renal transplant patients with long COVID-19

A new study has reported two renal transplant cases, in which individuals, after being exposed to remdesivir, developed a resistance to the drug.

1 Jul 2022

Casirivimab/imdevimab improve outcomes in early COVID-19

A new Viruses study determines the effect of casirivimab/imdevimab on IFN-1 and cytokines during SARS-CoV-2 infection.

29 Jun 2022

SARS-CoV-2 3CLpro also susceptible to mutations

Researchers assess the activity of all potential mutations in the SARS-CoV-2 3CLpro.

29 Jun 2022

Anticancer drug candidate that targets a human protein could be a pan-viral medication

More than two years into the COVID-19 pandemic, people are realizing that the "new normal" will probably involve learning to co-exist with SARS-CoV-2. Some treatments are available, but with new variants emerging, researchers are looking toward new strategies.

29 Jun 2022

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Researchers assessed the in vivo effectiveness of monoclonal antibodies and directly acting antiviral agents against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages.

28 Jun 2022

A cancer patient who had SARS-CoV-2 for over eight months

In a recent study posted to the medRxiv* pre-print server, researchers in Israel described the case of a severely immunocompromised cancer patient who developed a chronic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

28 Jun 2022

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Rensselaer Polytechnic Institute researchers Gaetano Montelione and Christopher Cioffi will use a five-year, $3.5 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop a low-dose, oral COVID antiviral drug that can be administered at home.

27 Jun 2022

Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening

Scientists have described the development of a modified A549 cell line that shows a robust expression of ACE2 and TMPRSS2 and high susceptibility to SARS-CoV-2 infection.

24 Jun 2022

Insufficient drug exposure most likely to cause COVID-19 rebound

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals.

21 Jun 2022

Emory researchers identify key immune cell type that drives the transition from early to late COVID-19

Determining how SARS-CoV-2, the virus causing COVID-19, moves from an early stage of infection, when patients are largely asymptomatic, into a later stage when people may experience life-threatening inflammation in the lungs, is a critical step in understanding how to target and treat the disease more efficiently.

14 Jun 2022

Study investigates SARS-CoV-2 escape from nirmatrelvir

Researchers assessed SARS-CoV-2 Alpha, Delta, and Omicron variants’ resistance to nirmatrelvir, a protease inhibitor of SARS-CoV-2.

10 Jun 2022

Remdesivir News and Research

Scientists introduce SARS-CoV-2 phenotype screening for identifying novel antiviral drugs

Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

Should siRNA-based antivirals be added to the COVID toolbox?

Nitazoxanide drug found to be a potent inhibitor of several human coronaviruses

New approach could pave the way for development of pan-coronavirus antivirals

The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients

Does high-dose inhaled nitric oxide improve respiratory function and outcomes among pregnant patients hospitalized with severe COVID-19 pneumonia?

Monoclonal antibody treatment taken by hospitalized COVID-19 patients reduces mortality

Study examines IMPACC trial results to understand clinical phenotypes of disease severity in hospitalized COVID-19 patients

Remdesivir resistance in renal transplant patients with long COVID-19

Casirivimab/imdevimab improve outcomes in early COVID-19

SARS-CoV-2 3CLpro also susceptible to mutations

Anticancer drug candidate that targets a human protein could be a pan-viral medication

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

A cancer patient who had SARS-CoV-2 for over eight months

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening

Insufficient drug exposure most likely to cause COVID-19 rebound

Emory researchers identify key immune cell type that drives the transition from early to late COVID-19

Study investigates SARS-CoV-2 escape from nirmatrelvir

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News